EmaxHealth

Health knowledge and news provided by doctors.

Ads by Google

Colon Cancer

Colon cancer - malignant disease, which can be located in any part of the large intestine, in the tissues of colon. EmaxHealth covers the latest news on signs, symptoms and treatment of colon and rectal cancers.

Celator Announces Trial Results For CPX-1 In Colorectal Cancer Treatment

Celator Pharmaceuticals reported positive results from its CPX-1 Phase 2 clinical trial in patients with advanced colorectal cancer. CPX-1 is a liposomal formulation of irinotecan and floxuridine, based on the company's proprietary CombiPlex technology. The results were presented in a poster presentation at the American Society of Clinical Oncology meeting in Chicago.

conditions: 

GeneNews Reports Positive Results From Colorectal Cancer Study

GeneNews reported positive performance results from a large validation study of a six-gene biomarker panel for the assessment of a patient's current risk for colorectal cancer. This panel forms the basis of the Company's lead product, ColonSentry, which is planned for launch in Canada in the third quarter of 2008 as a laboratory-developed test.

The validation study confirmed (p less than 0.05) that the panel was able to stratify a population with average risk for colorectal cancer into three groups:

-

conditions: 

Perioperative Eloxatin Regimen Reduced Risk Of Relapse In Colorectal Cancer Patients

In eligible patients Eloxatin in combination with 5-fluorouracil/leucovorin significantly improved three-year PFS compared to surgery alone when given perioperatively to colorectal cancer patients with initially resectable liver metastases.

conditions: 

ANAVEX 7-1037 Demonstrates Chemotherapeutic Potential For Treatment Of Colorectal Cancer

Anavex Life Sciences announced that ANAVEX 7-1037 has been shown to kill human HCT116 colon cancer cells in advanced pre-clinical studies. In addition, ANAVEX 7-1037 demonstrated its ability to significantly suppress tumor growth in immune-deficient mice. ANAVEX 7-1037 is the company's lead drug candidate for the treatment of colorectal cancer and other types of solid tumors.

conditions: 

CC Detect - Serum-Based Diagnostic Test For Colon Cancer Available

CC Detect, Panacea Pharmaceuticals's serum- based colon cancer diagnostic test, is now available from Panacea Laboratories. CC Detect is a simple blood test that should facilitate the identification of individuals with cancer of the colon and rectum when used in conjunction with standard screening methods. Panacea Laboratories, a division of Panacea Pharmaceuticals, is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The blood sample can be ordered by any physician and sent to Panacea for testing.

conditions: 

Pages